Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers

Pierre‐Emmanuel Sugier & Alexis Elbaz et al. · 2023-02-14

Abstract

Background

Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties.

Objective

We used results from genome‐wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors.

Methods

We used individual data for participants of European ancestry from the Courage‐PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta‐Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa, using cross‐phenotypes polygenic risk score (PRS) analyses.

Results

We confirmed a previously reported positive genetic correlation of PD with melanoma (Gcorr = 0.16 [0.04; 0.28]) and reported an additional significant positive correlation of PD with prostate cancer (Gcorr = 0.11 [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the NSF gene (17q21.31).

Conclusions

We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Funding
NIH Grant U01‐CA98710NIHR FundingPancreatic Cancer UK FundingRoseTrees trust FundingThe contribution of RAD51C and RAD51D to breast and ovarian cancerCancer Research UK (CRUK) Grant C12292/A11174NIH HHS Grant U01-CA98233Department of Health FundingIntegrative Analysis of Lung Cancer Etiology and RiskImputation-based approach to identify low frequency variants in prostate cancerCancer Research UK Grant A8197/A16565Cancer Research UK (CRUK) Grant C5047/A10692Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3Discovery, Biology and Risk of Inherited Variants in Breast CancerNCI NIH HHS Grant NIH NCI U01 CA188392Cancer Research UK Grant C16913/A6135NIH HHS Grant NIH U19 CA203654Susan G. Komen FundingCancer Research UK Grant C5047/A3354NIH HHS Grant U01-CA98710Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3NHLBI NIH HHS Grant HHSN268201200008CCancer Research UK Grant C5047/A33Cancer Research UK Grant C5047/A7357Cancer Research UK (CRUK) Grant C5047/A8384A genome-wide association study for breast cancer in BRCA1 mutation carriersCancer Research UK (CRUK) Grant C1287/A10118Elucidating Loci Involved in Prostate Cancer SuceptibilityNational Institutes of Health (NIH) Grant X01HG007492Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3NHGRI NIH HHS FundingA genome-wide association study for breast cancer in BRCA1 mutation carriersFollow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI)Cancer Research UK (CRUK) Grant C1281/A12014Cancer Research UK Grant C1281Cancer Research UK (CRUK) Grant C1287/A10710NHLBI NIH HHS Grant HHSN268201200008IWorld Health Organization Grant 001Cancer Research UK (CRUK) Grant C1287/A16563Wellcome Trust Grant 209057Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.Breast Cancer Research Foundation FundingCanadian Institutes of Health Research FundingCancer Council Victoria FundingEU Joint Programme – Neurodegenerative Disease Research FundingEuropean Commission Grant H2020 633784European Commission Grant H2020 634935FP7 Health FundingGovernment of Canada FundingInstitut National de la Sant? et de la Recherche M?dicale FundingInstitute of Cancer Research FundingLigue Contre le Cancer FundingNational Cancer Research Institute FundingNational Human Genome Research Institute FundingMolecular Immunology CoreNIH Grant HHSN268201200008INIH Grant U01‐CA98233Seventh Framework Programme Grant HEALTH‐F2‐2009‐223175Vetenskapsrådet Grant K2010‐70X‐20430‐04‐VicHealth FundingINCA Grant 9533ARC Grant PGA120150202302

NCI NIH HHS

R01 CA225662

NCI NIH HHS

U01 CA098758

NCI NIH HHS

U19 CA148065

NCI NIH HHS

U01 CA098216

NCI NIH HHS

R01 CA128978

NCI NIH HHS

U19 CA148537

NCI NIH HHS

U01 CA098233

NIH HHS

CA128978

NCI NIH HHS

U19 CA148112

NCI NIH HHS

U01 CA098710

NIH

1U19

NIH

CA128978

NIH

U19 CA148065